Boule Diagnostics AB Total Liabilities
Boule Diagnostics AB total liabilities. Based on the latest financial reports, Boule Diagnostics AB (BOUL) has total liabilities worth Skr303.90 Million SEK (≈ $32.70 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Boule Diagnostics AB's assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Boule Diagnostics AB (2005–2024)
Total liabilities of Boule Diagnostics AB from 2005 to 2024. This chart illustrates how Boule Diagnostics AB's total liabilities have evolved over time, based on quarterly financial data. Explore Boule Diagnostics AB long-term investment intensity to see how much of total assets are deployed in long-term investments.
Boule Diagnostics AB Competitors by Total Liabilities
The table below lists competitors of Boule Diagnostics AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Opawica Explorations Inc
V:OPW
|
Canada | CA$870.04K |
|
Maxeon Solar Technologies Ltd
NASDAQ:MAXN
|
USA | $507.96 Million |
|
Qlife Holding AB
ST:QLIFE
|
Sweden | Skr12.89 Million |
|
Caledonia Mining Corporation Plc
LSE:CMCL
|
UK | GBX116.79 Million |
|
XORTX Therapeutics Inc
V:XRTX
|
Canada | CA$837.41K |
|
Sure-Tech Investments LP
TA:STEC
|
Israel | ILA1.31 Million |
|
Ibstock PLC
LSE:IBST
|
UK | GBX395.74 Million |
Liability Composition Analysis (2005–2024)
This chart breaks down Boule Diagnostics AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see BOUL current and non-current assets.
Liquidity & Leverage Metrics
Boule Diagnostics AB Total Liabilities Ratios Explained
Boule Diagnostics AB total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.10 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.88 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.65 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Boule Diagnostics AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Boule Diagnostics AB (2005–2024)
The table below shows the annual total liabilities of Boule Diagnostics AB from 2005 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr320.60 Million ≈ $34.50 Million |
+14.50% |
| 2023-12-31 | Skr280.01 Million ≈ $30.13 Million |
-5.87% |
| 2022-12-31 | Skr297.46 Million ≈ $32.01 Million |
+7.66% |
| 2021-12-31 | Skr276.30 Million ≈ $29.73 Million |
+31.32% |
| 2020-12-31 | Skr210.41 Million ≈ $22.64 Million |
-17.16% |
| 2019-12-31 | Skr254.00 Million ≈ $27.33 Million |
+27.00% |
| 2018-12-31 | Skr199.99 Million ≈ $21.52 Million |
+29.26% |
| 2017-12-31 | Skr154.72 Million ≈ $16.65 Million |
+14.98% |
| 2016-12-31 | Skr134.57 Million ≈ $14.48 Million |
+5.98% |
| 2015-12-31 | Skr126.97 Million ≈ $13.66 Million |
+15.47% |
| 2014-12-31 | Skr109.96 Million ≈ $11.83 Million |
+17.95% |
| 2013-12-31 | Skr93.23 Million ≈ $10.03 Million |
+23.42% |
| 2012-12-31 | Skr75.54 Million ≈ $8.13 Million |
-4.37% |
| 2011-12-31 | Skr78.99 Million ≈ $8.50 Million |
+4.55% |
| 2010-12-31 | Skr75.55 Million ≈ $8.13 Million |
+55.85% |
| 2009-12-31 | Skr48.47 Million ≈ $5.22 Million |
-8.79% |
| 2008-12-31 | Skr53.14 Million ≈ $5.72 Million |
+3.61% |
| 2007-12-31 | Skr51.29 Million ≈ $5.52 Million |
+10.69% |
| 2006-12-31 | Skr46.34 Million ≈ $4.99 Million |
+9.63% |
| 2005-12-31 | Skr42.27 Million ≈ $4.55 Million |
-- |
About Boule Diagnostics AB
Boule Diagnostics AB (publ) develops, manufactures, and markets instruments and consumable products for blood diagnostics in the United States of America, Asia, Eastern Europe, Latin America, Western Europe, Africa, and the Middle East. The company provides hematology analyzers, reagents, controls, and calibrators, under the Swelab, Medonic, and Quintus brands; and veterinary hematology and clini… Read more